The US Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration issued a ‘pause’ recommendation for future vaccinations in the USA with the experimental Johnson & Johnson – Janssen COVID-19 Vaccine.
UPDATE: A virtual emergency meeting of the CDC's ACIP will be held to discuss the Janssen COVID-19 vaccine on April 23, 2021, from 11:00 a.m. to 5:00 p.m. ET.
J&J COVID-19 Vaccinations Paused in the USA
Rare Thrombosis, Thrombocytopenia Seen After AstraZeneca COVID-19 Vaccine
Reports document 16 reactions in young European patients following first dose of ChAdOx1 nCoV-19 vaccine
Excellent Outcomes Found for Neonates Born to SARS-CoV-2-Postive Moms
Most neonates fed unpasteurized expressed breast milk until discharge; 85 percent were breastfed postdischarge
FDA, CDC Call for Pause in J&J COVID-19 Vaccine After Six People Develop Clots
The six cases involved a cerebral venous sinus thrombosis and occurred in women between the ages of 18 and 48 years
COVID-19 Infection May Up Mortality in Surgical Patients
Authors recommend postponing surgery for patients with positive preoperative COVID-19 test result
WHO Urges Halt to Sale of Live Wild Animals at Food Markets
Agency says wild animals ‘are the source of more than 70 percent of all emerging infectious diseases in humans’
Restrictions on Access to Abortion Pill Will Be Lifted During Pandemic
Decision means that health care providers in some states will be able to prescribe mifepristone via telemedicine and mail the pills to patients
Diabetes Drug Found Ineffective Against COVID-19
AstraZeneca and Saint Luke’s Mid America Heart Institute announced high-level results of the DARE-19 Phase III trial assessing the potential of Farxiga to treat patients hospitalized with COVID-19 who are at risk of developing serious complications.
The companies confirmed on April 12, 2021, this trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death) at 30 days.
Skin Reactions Usually Mild After COVID-19 Vaccination
Most common were delayed large local reactions, followed by local injection site reactions, urticarial eruptions, morbilliform eruptions
Blood Clot Risk High Following COVID-19 Hospitalization
However, anticoagulation cuts risk for major thromboembolic events by 46 percent